Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab DDI Study in Psoriasis
NCT02993471Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2016
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ixekizumab in plaque psoriasis (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 (CYP450) Substrate-Midazolam, Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Midazolam and 8 more. Started Dec 2016; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02993471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993471.